|
1
|
Ottaviani G and Jaffe N: The etiology of
osteosarcoma. Cancer Treat Res. 152:15–32. 2009. View Article : Google Scholar
|
|
2
|
Berner K, Hall KS, Monge OR, Weedon-Fekjær
H, Zaikova O and Bruland OS: Prognostic factors and treatment
results of high-grade osteosarcoma in norway: A scope beyond the
'classical' patient. Sarcoma. 2015:5168432015. View Article : Google Scholar
|
|
3
|
Li J, Yang Z, Li Y, Xia J, Li D, Li H, Ren
M, Liao Y, Yu S, Chen Y, et al: Cell apoptosis, autophagy and
necroptosis in osteosarcoma treatment. Oncotarget. 7:44763–44778.
2016.PubMed/NCBI
|
|
4
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eftekhari F: Imaging assessment of
osteosarcoma in childhood and adolescence: Diagnosis, staging, and
evaluating response to chemotherapy. Cancer Treat Res. 152:33–62.
2009. View Article : Google Scholar
|
|
6
|
Salah S, Ahmad R, Sultan I, Yaser S and
Shehadeh A: Osteosarcoma with metastasis at initial diagnosis:
Current outcomes and prognostic factors in the context of a
comprehensive cancer center. Mol Clin Oncol. 2:811–816. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment - where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar
|
|
8
|
Errani C, Longhi A, Rossi G, Rimondi E,
Biazzo A, Toscano A, Alì N, Ruggieri P, Alberghini M, Picci P, et
al: Palliative therapy for osteosarcoma. Expert Rev Anticancer
Ther. 11:217–227. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schwarz R, Bruland O, Cassoni A, Schomberg
P and Bielack S: The role of radiotherapy in oseosarcoma. Cancer
Treat Res. 152:147–164. 2009. View Article : Google Scholar
|
|
10
|
Meyers PA, Schwartz CL, Krailo MD, Healey
JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM,
Harris M, et al Children's Oncology Group: Osteosarcoma: The
addition of muramyl tripeptide to chemotherapy improves overall
survival: A report from the Children's Oncology Group. J Clin
Oncol. 26:633–638. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chou AJ, Kleinerman ES, Krailo MD, Chen Z,
Betcher DL, Healey JH, Conrad EU III, Nieder ML, Weiner MA, Wells
RJ, et al Children's Oncology Group: Addition of muramyl tripeptide
to chemotherapy for patients with newly diagnosed metastatic
osteosarcoma: A report from the Children's Oncology Group. Cancer.
115:5339–5348. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Skinner R, Cotterill SJ and Stevens MC;
United Kingdom Children's Cancer Study Group: Risk factors for
nephrotoxicity after ifosfamide treatment in children: A UKCCSG
Late Effects Group study. Br J Cancer. 82:1636–1645.
2000.PubMed/NCBI
|
|
13
|
Arunkumar PA, Viswanatha GL, Radheshyam N,
Mukund H and Belliyappa MS: Science behind cisplatin-induced
nephrotoxicity in humans: A clinical study. Asian Pac J Trop
Biomed. 2:640–644. 2012. View Article : Google Scholar
|
|
14
|
Davies JT, Delfino SF, Feinberg CE,
Johnson MF, Nappi VL, Olinger JT, Schwab AP and Swanson HI: Current
and emerging uses of statins in clinical therapeutics: A Review.
Lipid Insights. 9:13–29. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jeon CY, Pandol SJ, Wu B, Cook-Wiens G,
Gottlieb RA, Merz CN and Goodman MT: The association of statin use
after cancer diagnosis with survival in pancreatic cancer patients:
A SEER-medicare analysis. PLoS One. 10:e01217832015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mei Z, Liang M, Li L, Zhang Y, Wang Q and
Yang W: Effects of statins on cancer mortality and progression: A
systematic review and meta-analysis of 95 cohorts including
1,111,407 individuals. Int J Cancer. 140:1068–1081. 2017.
View Article : Google Scholar
|
|
17
|
Relja B, Meder F, Wang M, Blaheta R,
Henrich D, Marzi I and Lehnert M: Simvastatin modulates the
adhesion and growth of hepatocellular carcinoma cells via decrease
of integrin expression and ROCK. Int J Oncol. 38:879–885. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Relja B, Meder F, Wilhelm K, Henrich D,
Marzi I and Lehnert M: Simvastatin inhibits cell growth and induces
apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int
J Mol Med. 26:735–741. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Woschek M, Kneip N, Jurida K, Marzi I and
Relja B: Simvastatin reduces cancerogenic potential of renal cancer
cells via heranylgeranyl pyrophosphate and mevalonate pathway. Nutr
Cancer. 68:420–427. 2016. View Article : Google Scholar
|
|
20
|
Mullen PJ, Yu R, Longo J, Archer MC and
Penn LZ: The interplay between cell signalling and the mevalonate
pathway in cancer. Nat Rev Cancer. 16:718–731. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou Q and Liao JK: Statins and
cardiovascular diseases: From cholesterol lowering to pleiotropy.
Curr Pharm Des. 15:467–478. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Klein MS, Koffarnus RL, Minze MG and Ochoa
P: Achieving cholesterol goals with low-cost
3-hydroxy-3-methylglutaryl coenzyme-A (HMG Co-A) reductase
inhibitors. Am J Health Syst Pharm. 73(Suppl 1): S63–S68. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tricarico PM, Crovella S and Celsi F:
Mevalonate pathway blockade, mitochondrial dysfunction and
autophagy: A possible link. Int J Mol Sci. 16:16067–16084. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garay T, Kenessey I, Molnár E, Juhász É,
Réti A, László V, Rózsás A, Dobos J, Döme B, Berger W, et al:
Prenylation inhibition-induced cell death in melanoma: Reduced
sensitivity in BRAF mutant/PTEN wild-type melanoma cells. PLoS One.
10:e01170212015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wood CE, Hukkanen RR, Sura R,
Jacobson-Kram D, Nolte T, Odin M and Cohen SM: Scientific and
Regulatory Policy Committee (SRPC) Review: Interpretation and use
of cell proliferation data in cancer risk assessment. Toxicol
Pathol. 43:760–775. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao XH, Xu ZR, Zhang Q and Yang YM:
Simvastatin protects human osteosarcoma cells from oxidative
stress-induced apoptosis through mitochondrial-mediated signaling.
Mol Med Rep. 5:483–488. 2012.
|
|
27
|
Fromigué O, Haÿ E, Modrowski D, Bouvet S,
Jacquel A, Auberger P and Marie PJ: RhoA GTPase inactivation by
statins induces osteosarcoma cell apoptosis by inhibiting
p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell
differentiation. Cell Death Differ. 13:1845–1856. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sandoval-Usme MC, Umaña-Pérez A, Guerra B,
Hernández-Perera O, García-Castellano JM, Fernández-Pérez L and
Sánchez-Gómez M: Simvastatin impairs growth hormone-activated
signal transducer and activator of transcription (STAT) signaling
pathway in UMR-106 osteosarcoma cells. PLoS One. 9:e877692014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kamel WA, Sugihara E, Nobusue H,
Yamaguchi-Iwai S, Onishi N, Maki K, Fukuchi Y, Matsuo K, Muto A,
Saya H, et al: Simvastatin-induced apoptosis in osteosarcoma cells:
A Key role of RhoA-AMPK/p38 MAPK signaling in antitumor activity.
Mol Cancer Ther. 16:182–192. 2017. View Article : Google Scholar
|
|
30
|
Björkhem-Bergman L, Lindh JD and Bergman
P: What is a relevant statin concentration in cell experiments
claiming pleiotropic effects? Br J Clin Pharmacol. 72:164–165.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
No authors listed. Randomised trial of
cholesterol lowering in 4444 patients with coronary heart disease:
The Scandinavian Simvastatin Survival Study (4S). Lancet.
344:1383–1389. 1994.PubMed/NCBI
|
|
32
|
Heart Protection Study Collaborative
Group: MRC/BHF Heart Protection Study of cholesterol lowering with
simvastatin in 20,536 high-risk individuals: A randomised
placebo-controlled trial. Lancet. 360:7–22. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
van der Spek E, Bloem AC, van de Donk NW,
Bogers LH, van der Griend R, Kramer MH, de Weerdt O, Wittebol S and
Lokhorst HM: Dose-finding study of high-dose simvastatin combined
with standard chemotherapy in patients with relapsed or refractory
myeloma or lymphoma. Haematologica. 91:542–545. 2006.PubMed/NCBI
|
|
34
|
Fulda S: The mechanism of necroptosis in
normal and cancer cells. Cancer Biol Ther. 14:999–1004. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fulda S: Targeting apoptosis for
anticancer therapy. Semin Cancer Biol. 31:84–88. 2015. View Article : Google Scholar
|
|
36
|
Jendrossek V: The intrinsic apoptosis
pathways as a target in anticancer therapy. Curr Pharm Biotechnol.
13:1426–1438. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Andrabi SA, Kim NS, Yu SW, Wang H, Koh DW,
Sasaki M, Klaus JA, Otsuka T, Zhang Z, Koehler RC, et al:
Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad
Sci USA. 103:18308–18313. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kroemer G, Galluzzi L and Brenner C:
Mitochondrial membrane permeabilization in cell death. Physiol Rev.
87:99–163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Spampanato C, De Maria S, Sarnataro M,
Giordano E, Zanfardino M, Baiano S, Cartenì M and Morelli F:
Simvastatin inhibits cancer cell growth by inducing apoptosis
correlated to activation of Bax and downregulation of BCL-2 gene
expression. Int J Oncol. 40:935–941. 2012. View Article : Google Scholar
|
|
40
|
Konturek PC, Burnat G and Hahn EG:
Inhibition of Barret's adenocarcinoma cell growth by simvastatin:
Involvement of COX-2 and apoptosis-related proteins. J Physiol
Pharmacol. 58(Suppl 3): 141–148. 2007.PubMed/NCBI
|
|
41
|
Lee HY, Kim IK, Lee HI, Mo JY, Yeo CD,
Kang HH, Moon HS and Lee SH: The apoptotic effect of simvastatin
via the upregulation of BIM in nonsmall cell lung cancer cells. Exp
Lung Res. 42:14–23. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Giotakis AI, Kontos CK, Manolopoulos LD,
Sismanis A, Konstadoulakis MM and Scorilas A: High BAX/BCL2 mRNA
ratio predicts favorable prognosis in laryngeal squamous cell
carcinoma, particularly in patients with negative lymph nodes at
the time of diagnosis. Clin Biochem. 49:890–896. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
O'Connor MJ: Targeting the DNA damage
response in cancer. Mol Cell. 60:547–560. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bendris N, Lemmers B and Blanchard JM:
Cell cycle, cyto-skeleton dynamics and beyond: The many functions
of cyclins and CDK inhibitors. Cell Cycle. 14:1786–1798. 2015.
View Article : Google Scholar :
|
|
45
|
Dey N, Williams C, Leyland-Jones B and De
P: Mutation matters in precision medicine: A future to believe in.
Cancer Treat Rev. 55:136–149. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Babcook MA, Sramkoski RM, Fujioka H,
Daneshgari F, Almasan A, Shukla S, Nanavaty RR and Gupta S:
Combination simvastatin and metformin induces G1-phase cell cycle
arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous
metastatic castration-resistant prostate cancer cells. Cell Death
Dis. 5:e15362014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Schointuch MN, Gilliam TP, Stine JE, Han
X, Zhou C, Gehrig PA, Kim K and Bae-Jump VL: Simvastatin, an
HMG-CoA reductase inhibitor, exhibits anti-metastatic and
anti-tumorigenic effects in endometrial cancer. Gynecol Oncol.
134:346–355. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Masuda H, Miller C, Koeffler HP, Battifora
H and Cline MJ: Rearrangement of the p53 gene in human osteogenic
sarcomas. Proc Natl Acad Sci USA. 84:7716–7719. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mirabello L, Yeager M, Mai PL,
Gastier-Foster JM, Gorlick R, Khanna C, Patiño-Garcia A,
Sierrasesúmaga L, Lecanda F, Andrulis IL, et al: Germline TP53
variants and susceptibility to osteosarcoma. J Natl Cancer Inst.
107:1072015. View Article : Google Scholar
|
|
50
|
Goto A, Kanda H, Ishikawa Y, Matsumoto S,
Kawaguchi N, Machinami R, Kato Y and Kitagawa T: Association of
loss of heterozygosity at the p53 locus with chemoresistance in
osteosarcomas. Jpn J Cancer Res. 89:539–547. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chen Z, Guo J, Zhang K and Guo Y: TP53
mutations and survival in osteosarcoma patients: A meta-analysis of
published data. Dis Markers. 2016:46395752016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Williams GH and Stoeber K: The cell cycle
and cancer. J Pathol. 226:352–364. 2012. View Article : Google Scholar
|
|
53
|
Liang SL, Liu H and Zhou A:
Lovastatin-induced apoptosis in macrophages through the
Rac1/Cdc42/JNK pathway. J Immunol. 177:651–656. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ogawa E, Okuyama R, Egawa T, Nagoshi H,
Obinata M, Tagami H, Ikawa S and Aiba S: p63/p51-induced onset of
keratinocyte differentiation via the c-Jun N-terminal kinase
pathway is counteracted by keratinocyte growth factor. J Biol Chem.
283:34241–34249. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Dhanasekaran DN and Reddy EP: JNK
signaling in apoptosis. Oncogene. 27:6245–6251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Fromigué O, Hamidouche Z and Marie PJ:
Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces
osteosarcoma cell invasion. J Biol Chem. 283:30549–30556. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhu Y, Casey PJ, Kumar AP and Pervaiz S:
Deciphering the signaling networks underlying simvastatin-induced
apoptosis in human cancer cells: Evidence for non-canonical
activation of RhoA and Rac1 GTPases. Cell Death Dis. 4:e5682013.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sassano A, Katsoulidis E, Antico G, Altman
JK, Redig AJ, Minucci S, Tallman MS and Platanias LC: Suppressive
effects of statins on acute promyelocytic leukemia cells. Cancer
Res. 67:4524–4532. 2007. View Article : Google Scholar : PubMed/NCBI
|
